Waters Corp ( (WAT) ) has released its Q4 earnings. Here is a breakdown of the information Waters Corp presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Waters Corporation is a global leader in analytical instruments and software, serving the life, materials, food, and environmental sciences, with a reputation for ensuring the efficacy of medicines and the safety of food and water across more than 100 countries.
In its latest earnings report, Waters Corporation revealed impressive financial results for the fourth quarter and full-year 2024, exceeding expectations despite challenges from foreign exchange rates. The company highlighted strong growth in its pharmaceutical segment and increased adoption of its new products.
Key financial metrics for the fourth quarter show sales reaching $873 million, a 6% increase from the previous year, and a 13% growth in non-GAAP EPS to $4.10. Full-year sales were flat at $2,958 million, but the company achieved a non-GAAP EPS growth of 1% to $11.86, overcoming a 5% negative impact from currency fluctuations. The pharmaceutical market saw notable growth, with a 10% increase in constant currency terms.
Waters Corporation’s robust operational performance and strategic initiatives have positioned the company well for future growth. Despite external challenges such as foreign exchange headwinds and inflation, the company expanded its adjusted operating income margin to 31.0% for the year.
Looking ahead, Waters Corporation projects continued growth with full-year 2025 constant currency sales expected to increase by 4.5% to 7.0%. The company remains optimistic about its strategic direction and is well-prepared to navigate any upcoming challenges in the global market.
